INTRODUCTION
A key step during initiation of protein synthesis in eukaryotic cells is formation of the ternary complex (TC) composed of the translation initiation factor 2 (eIF2), GTP and initiator Met-tRNA i Met . The eIF2 itself is a heterotrimer of distinct ␣, ␤ and ␥ subunits. The eIF2 TC binds to the 40S small ribosomal subunit, along with other translation factors, forming a 43S preinitiation complex (PIC) that binds near the 5 end of a messenger RNA (mRNA) forming a 48S PIC. The 48S PIC then scans down the mRNA (1) . The translation start site, typically an AUG codon, is selected by base-pairing interactions between the anticodon of the tRNA i Met and the mRNA. Start codon selection triggers completion of GTP hydrolysis by eIF2, release of P i and subsequent release of eIF2-GDP (1) (2) (3) . In addition to mediating delivery of Met-tRNA i
Met to the ribosome, eIF2 also plays a critical role in selection of the translation start codon. Mutations have been isolated in all three subunits of yeast eIF2 that relax the stringency of start site selection and promote initiation at a near cognate start codon (4) (5) (6) (7) (8) . Recently, multiple cases of an X-linked intellectual disability (XLID) syndrome caused by mutations in the EIF2S3 gene, encoding the eIF2␥ subunit, have been identified (9) (10) (11) (12) . The acronym MEHMO denotes the characteristic symptoms of this syndrome: Mental deficiency, Epilepsy, Hypogenitalism, Microcephaly and Obesity (13) . While severely affected patients exhibit all symptoms, less affected patients exhibit only a subset of the symptoms. Furthermore, it remains unknown why symptom severity is variable between patients and how each of the identified mutations impacts eIF2 function. Thus, there is a critical need to determine the underlying molecular mechanism governing the phenotype of the MEHMO patients.
Genetic analyses of MEHMO syndrome patients have identified several unique mutations in EIF2S3 that map to distinct regions of eIF2␥ (9) (10) (11) , suggesting that the different mutations will likely impact distinct eIF2 functions. We previously characterized the MEHMO mutation I222T, located on the back face of the eIF2␥ GTP-binding domain ( Figure 1B ). This eIF2␥ -I222T mutation lies in a cleft that forms the docking site for helix ␣1 of eIF2␤. Accordingly, the eIF2␥ -I222T mutation impaired the interaction of overexpressed eIF2␥ with the endogenous eIF2␤ in human cells (9) . Likewise, mutation of the corresponding residue (V281) Met TC (PDB code 3V11; (25) ) using PyMOL software (Schrodinger). Components are colored as follows: tRNA i Met , green; Met, purple, aIF2␣, yellow; aIF2␤ helix ␣1, slate; GTP, gold and aIF2␥ , cyan. (B) Magnification of the aIF2␥ tRNA-binding pocket to highlight the proximity of SsI218 (HsI259, blue) to MettRNA i
Met . Sites of three other mutations identified in patients with MEHMO syndrome are highlighted in stick representation including SsI181 (HsI222, red), SsT69 (HsS108, brown) and a C-terminal frameshift mutation (orange). (C) Magnification of aIF2␥ from panel (B) . MEHMO syndrome mutation site SsI218 (ScI318, HsI259; blue) and the adjacent SsR219 (ScR319, HsR260; pink) residues are highlighted. (D) Residues forming the methionine (magenta) binding pocket in Saccharomyces cerevisiae eIF2␥ , taken from the structure of the yeast 48S PIC (PDB code 3JAP; (42) . (E) Serial dilutions of yeast strains expressing the indicated WT or mutant forms of eIF2␥ were spotted onto SD minimal medium containing essential amino acid supplements and plates were incubated at 30 • C for 2 days. (F) Whole cell extracts (WCEs) from yeast strains expressing the indicated wild-type or mutant forms of eIF2␥ were subjected to (SDS-PAGE) followed by immunoblotting with rabbit polyclonal antisera against yeast eIF2␥ or GCD6 (eIF2Bε).
in yeast eIF2␥ , encoded by the GCD11 gene, impaired eIF2␤ binding. In addition to impairing eIF2␤ binding to eIF2␥ , the V281T mutation in yeast eIF2␥ caused modest derepression of GCN4 expression, a sensitive reporter of eIF2 function in yeast, and impaired the stringency of translation start site selection in reporter gene experiments as revealed by increased initiation at a near cognate UUG codon. A second mutation linked to MEHMO syndrome, eIF2␥ -I465Sfs*4, is caused by a 4-nt deletion near the 3 end of the eIF2␥ open reading frame (10) (11) (12) . The mutation introduces a frameshift and changes the C-terminal residues of eIF2␥ . While the molecular defect associated with the I465Sfs*4 mutation has not been resolved, the corresponding mutation in yeast eIF2 derepresses GCN4 expression and decreases the stringency of translation start site selection (12) . A third mutation in EIF2S3 linked to MEHMO syndrome changed the poorly conserved S108 residue to arginine; however, it is unclear how this mutation impacts eIF2 function and the corresponding mutation in yeast eIF2␥ had no phenotype. Consistent with the lack of phenotype in yeast, the S108R mutation was associated with milder symptoms in the patient.
A fourth mutation in eIF2␥ -I259M, was identified in two male siblings with severe microcephaly, growth retardation, seizures and intellectual disability (10) , and thus likely also causes MEHMO syndrome. To gain insights into the molecular impact of the I259M mutation on eIF2 function, we mutated the corresponding residue (I318) in S. cerevisiae eIF2␥ . Our studies revealed that the I318M mutation in yeast eIF2␥ , like other MEHMO syndrome mutations in eIF2␥ , leads to derepressed GCN4 expression and relaxed stringency of translation start site selection in vivo. However, in contrast to the previously characterized MEHMO mutations in eIF2␥ , the I318M impairs Met-tRNA i Met binding to eIF2 both in vivo and in vitro. Thus, these studies provide insights into the structure-function properties of eIF2 and expand our understanding into the ways in which eIF2 function can be impaired to cause MEHMO syndrome.
MATERIALS AND METHODS

Yeast strains and plasmids
Yeast strain J292 (MATα leu2-3,-112 ura3-52 his3 gcn2Δ::loxP gcd11Δ::KanMX p[GCD11, URA3]) (5) was used for the analysis of eIF2␥ mutants. Mutant alleles of GCD11 were generated by site-directed mutagenesis and introduced into J292 as the sole source of eIF2␥ by plasmid shuffling (14) . Plasmids used in this study are listed in Table 1 .
Growth analysis
Derivatives of yeast strain J292 expressing WT or mutant forms of eIF2␥ , either alone or with an empty vector (pRS423) or various high copy-number plasmids to overexpress eIF2␣ (pC1682), eIF2␤ (pC4191) or tRNA i Met (pC1683), were grown to saturation in minimal SD medium with required amino acid supplements. Five microliter volumes of serial dilutions (OD 600 = 1.0, 0.1, 0.01, 0.001 and 0.0001) were spotted onto SD medium containing required 
Western blot analysis
Yeast strains expressing WT or mutant forms of eIF2␥ were grown to OD 600 ∼1 in 100 ml SD medium containing required amino acid supplements at 30
• C. Cells were harvested, washed with 5 ml Breaking Buffer A (20 mM Tris-HCl (pH 7.5), 500 mM KCl, 0.1 mM MgCl 2 , 5 mM ␤-mercaptoethanol, 10% (v/v) glycerol, 1× cOmplete protease inhibitor (Sigma-Aldrich) and 1 mM [4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), Sigma]), and resuspended in 1 ml Breaking Buffer A. Cells were lysed by adding 50% (w/v) glass beads and then vigorous mixing on a vortex for 5 min at 4
• C. Lysates were cleared by centrifugation at 15 700 × g for 10 min at 4
• C, quantified, mixed with sodium dodecyl sulphate (SDS)-sample buffer and incubated at 70
• C for 10 min. Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with rabbit polyclonal antisera against yeast eIF2␥ (15) , eIF2␤ (16) , eIF2␣ (17) and GCD6 (18) .
␤-galactosidase assays
For measurement of GCN4-lacZ, his4(UUG)-lacZ or HIS4(AUG)-lacZ expression, yeast cultures were grown overnight to saturation in SC medium and then used to inoculate 25 ml of SC medium at OD 600 = 0.25. Cultures were grown 6 h to OD 600 ≤1 and ␤-galactosidase activities were determined as previously described (19, 20) . Means and standard deviations of ␤-galactosidase activities were calculated for three independent transformants.
Cell culture and luciferase assays
HEK293T cells were obtained from American Type Culture Collection and maintained in Dulbecco Modified Eagle Medium (DMEM) containing 4.5 g/l D-glucose, Lglutamine and 110 mg/l sodium pyruvate (Gibco) that was supplemented with 10% Fetal Bovine Serum (FBS, Gibco) and 1% penicillin/streptomycin (Quality Biological). For measurements of ATF4-luc expression, ATF4-luc and a Renilla reporter plasmid were transiently co-transfected with an empty vector or overexpression plasmids encoding WT eIF2␥ or eIF2␥ -I259M into HEK293T cells following the Lipofectamine 3000 (Invitrogen) manufacturer's protocol. Culture media was exchanged for fresh DMEM medium 8 h after transfection. Cell lysis and measurement of relative luciferase activities were conducted following the Promega Dual-Luciferase Reporter Assay System protocol with a Centro XS LB 960 High Sensitivity Microplate Luminometer. Means and standard deviations of relative luciferase activities were calculated for three biological replicates.
eIF2 purification
Preparation of eIF2 was performed as previously described (21) with the following modifications. Yeast strains expressing WT eIF2␥ or eIF2␥ -I381M were grown to OD 600 ∼4 in 10 l yeast extract peptone dextrose (YPD) medium at 30
• C. Cells were pelleted by centrifugation at 6000 × g for 10 min at 4
• C, and cell pellets were frozen at −80 • C overnight. The following day, cells were lysed using a Waring Blender, 50% (w/v) glass beads, in 200 ml Lysis Buffer (75 mM Tris-HCl (pH 7.5), 100 mM KCl, 0.1 mM GDP, 14 mM ␤-mercaptoethanol and 1× cOmplete protease inhibitor (Roche)). Lysates were clarified by centrifugation at 15 000 × g for 30 min at 4
• C. The supernatant was transferred to a beaker and ammonium sulfate was added gradually to 75% saturation over 1 h at 4
• C. The slurry was then pelleted by centrifugation at 15 000 × g for 30 min at 4
• C, and the pellet was resuspended in Buffer A (20 mM Tris-HCl (pH 7.5), 0.5 M KCl, 0.1 mM MgCl 2 , 20 mM imidazole, 10% (v/v) glycerol, 10 M GDP, 5 mM ␤-mercaptoethanol and 1× cOmplete protease inhibitor). Following addition of 10 ml Ni-NTA resin (Qiagen), samples were stirred for 1 h at 4
• C. The Ni-NTA resin was subsequently washed with 30 ml Buffer A, and eIF2 complexes were eluted in 20 ml Buffer B (20 mM Tris-HCl (pH 7.5), 0.5 M KCl, 0.1 mM MgCl 2 , 500 mM imidazole, 10% (v/v) glycerol, 10 M GDP, 5 mM ␤-mercaptoethanol and 1× cOmplete protease inhibitor). The elute was dialyzed overnight against 0.5 l Dialysis Buffer (20 mM Tris-HCl (pH 7.5), 100 mM KCl, 0.1 mM MgCl 2 , 10% (v/v) glycerol, 10 M GDP and 2 mM dithiothreitol (DTT)) at 4
• C. Samples were then clarified by centrifugation at 4000 × g for 10 min at 4
• C, and the supernatant was passed through a 0.45 m filter to clear up the solution. Samples were loaded onto an equilibrated HiTrap Heparin column (Amersham) and further processed as described previously (21) . Fractions containing eIF2 were identified by SDS-PAGE, pooled, dialyzed against Storage Buffer (20 mM Tris-HCl (pH 7.5), 100 mM KAc, 0.1 mM MgAc, 10% (v/v) glycerol and 2 mM DTT), aliquoted and stored at −80
• C.
Synthesis and aminoacylation of tRNA i
Met
Yeast tRNA i Met was synthesized by in vitro transcription with T7 polymerase as described previously (21 Met was added to a final concentration of 1 nM and reactions were incubated for 15 min at 26
• C, followed by vacuum filtration as previously described (21) . For measurements of GDP affinity, final concentrations from 3.125 to 200 nM eIF2 were incubated for 15 min at 26
• C in Binding Assay Buffer lacking GDPNP-Mg 2+ . [ 3 H]GDP was added to a final concentration of 2 nM and reactions were incubated for 15 min at 26
• C followed by vacuum filtration as previously described (24 
eIF2␥ pull-down assay
Yeast strains expressing His-tagged forms of WT or mutant eIF2␥ , either alone or with an empty vector (pRS423) or high copy-number IMT4 (tRNA i Met ) plasmid (pC1683), were grown to OD 600 ∼ 1 in 200 ml SD medium with amino acid supplements at 30
• C. Cells were harvested, washed with 10 ml Breaking Buffer B (20 mM Tris-HCl (pH 7.5), 500 mM KCl, 0.1 mM MgCl 2 , 10 mM imidazole, 5 mM ␤-mercaptoethanol, 10% (v/v) glycerol, 1× cOmplete protease inhibitor and 1 mM AEBSF), and resuspended in 2 ml Breaking Buffer B. Cells were lysed by adding 50% (w/v) glass beads and then vigorous mixing on a vortex for 5 min at 4
• C. Lysates were cleared by centrifugation at 14 000 × g for 10 min at 4
• C and divided into quarters. For protein input samples, one quarter of the lysate was quantified, mixed with SDS-sample buffer and incubated at 70
• C for 10 min. For analysis of Met-tRNA i Met in input samples, one quarter of the lysate was quantified and subjected to RNA isolation using TRIzol LS Reagent (Invitrogen), followed by reverse transcriptase-polymerase chain reaction (RT-PCR) as described below. For eIF2␥ pull-down analysis, two quarters of the lysate were independently mixed with 0.1 ml Ni-NTA resin, incubated with slow rocking on a nutator for 2 h at 4
• C and then washed three times with 5 ml Breaking Buffer B. Beads were then either mixed with SDS-sample buffer or with TRIzol LS Reagent. Input and pull-down protein samples were subjected to SDS-PAGE Nucleic Acids Research, 2019, Vol. 47, No. 2 859 followed by immunoblotting with rabbit polyclonal antisera against yeast eIF2␥ , eIF2␤ and eIF2␣.
For analysis of Met-tRNA i Met , RNA was extracted from the input and pull-down samples using TRIzol LS Reagent (Invitrogen) according to the manufacture's protocol. Reverse transcription (RT) was conducted using SuperScript III First-Strand Synthesis SuperMix (ThermoFisher Scientific) with random hexamers according to the manufacturer's protocol. For RT reactions, 2.5 l RNA was utilized for input samples and all of the isolated RNA was utilized for pull-down samples. PCR reactions of input and pull-down samples were conducted using Phusion Hot Start II DNA Polymerase (ThermoFisher Scientific), 1× Phusion HF buffer, 200 M deoxynucleotide triphosphates (dNTPs), 0.5 M Forward Primer (5 -GCAGGGCTCAT AACCCTGAT-3 ), 0.5 M Reverse Primer (5 -TAGCG CCGCTCGGTTTC-3 ) and 1 l RT products in 50 l total volume. PCR was performed under the following conditions: (i) 98
• C for 30 s; (ii) 15 cycles of 98
• C for 10 s, 59
• C for 30 s and 72
• C for 2 s; and (iii) 72
• C for 5 min. Reactions products were resolved by electrophoresis on a 2.5% agarose gel and stained with GelRed Nucleic Acid Stain (Biotium).
RESULTS
MEHMO syndrome mutation eIF2␥-I259M lies in the MettRNA i Met -binding pocket and the corresponding I318M mutation in yeast eIF2␥ impairs cell growth
Recent X-chromosome exome sequencing identified a missense mutation (I259M) in the EIF2S3 gene encoding eIF2␥ of two male siblings with MEHMO syndrome phenotypes, including severe microcephaly, growth retardation, seizures and intellectual disability (10) . The I259 residue is located in domain II of eIF2␥ and is conserved among archaeal aIF2␥ and eukaryotic eIF2␥ proteins, suggesting that the residue could be of functional importance. Both eIF2␥ and the eIF2 complex are well conserved through evolution and structural studies on aIF2 and eIF2 complexes provide useful insights into the structure of human eIF2. Highresolution structures of the aIF2 TC, as well as of the yeast 48S PIC, reveal interactions among the eIF2␣, eIF2␤ and eIF2␥ subunits that mediate eIF2 heterotrimer formation as well as the interactions between Met-tRNA i Met and the eIF2 heterotrimer.
Based on the crystal structure of the Sulfolobus solfataricus (Ss ) aIF2 TC, composed of aIF2␣, aIF2␤, aIF2␥ , GTP and Met-tRNA i Met ( Figure 1A ) (25) , the Ile218 residue in aIF2␥ , which is analogous to the Ile259 mutation site in Homo sapiens eIF2␥ and I318 in S. cerevisiae eIF2␥ , lies in the tRNA-binding pocket of aIF2␥ ( Figure 1B and C) . Intriguingly, I218 in aIF2 is only ∼7Å from the methionine residue on Met-tRNA i Met , and the adjacent residue R219 makes direct contacts with the Met residue ( Figure 1C ). The proximity of I218 to a contact point with Met-tRNA i Met raises the possibility that the I259M mutation in the patients with MEHMO syndrome phenotypes might impair eIF2 TC formation by disrupting initiator Met-tRNA i Met binding to the eIF2 complex.
As it is challenging to study eIF2 mutations in mammalian systems, in part, because it has not been possible to prepare recombinant forms of mammalian eIF2
for biochemical studies, we use in vivo assays in S. cerevisiae and complementary biochemical experiments with purified wild-type and mutant yeast factors to study the impact of mutations on eIF2 function. Growth analyses were conducted for yeast strains lacking the chromosomal GCD11 gene encoding eIF2␥ and expressing wild-type (WT) eIF2␥ , eIF2␥ -V281T, eIF2␥ -V281K, eIF2␥ -I318M or eIF2␥ -I318L from a single copy-number plasmid. As shown previously (9) the V281T mutation, corresponding to the I222T mutation identified in a patient with MEHMO syndrome, had no impact on yeast cell growth compared to cells expressing WT eIF2␥ ( Figure 1E, rows 1 and 2) ; however, the Lys mutation at the same site (V281K) substantially impaired growth ( Figure 1E , rows 1 and 3) consistent with its more severe impact on eIF2␤ binding to eIF2␥ (9) . The I318M mutation in yeast eIF2␥ , corresponding to the I259M mutation in the patient, also resulted in a marked slow-growth phenotype ( Figure 1E, row 4) . In contrast, the I318L mutation did not impact yeast cell growth ( Figure 1E , row 5). Western analyses revealed similar levels of eIF2␥ in the strains, indicating that the growth defect in the strain expressing eIF2␥ -I318M is due to impaired eIF2␥ function and not to altered eIF2␥ levels ( Figure 1F ).
The eIF2␥-I318M mutation derepresses GCN4 reporter expression and reduces start codon selection stringency
To further explore how the I318M mutation disrupts eIF2␥ function, we examined translational control of a GCN4 reporter in the yeast strains expressing WT or mutant forms of eIF2␥ . GCN4 is a transcriptional activator whose synthesis is governed by regulated translation reinitiation at upstream open reading frames (uORFs) in the leader of the mRNA (Figure 2A , top) and by changes in eIF2 TC levels. Under nonstarvation conditions, where TC levels are high, ribosomes translate the first uORF (uORF1). Following termination at the uORF1 stop codon, the 40S ribosomal subunit resumes scanning. A TC readily binds the scanning 40S subunit enabling reinitiation at one of the subsequent inhibitory uORFs (uORFs2-4), which prevents ribosomes from scanning to the GCN4 main ORF (mORF) and synthesizing GCN4 protein. Under amino acid starvation conditions, a cellular stress-response process known as general amino acid control is triggered. The protein kinase GCN2 is activated and phosphorylates eIF2␣, converting eIF2 from a substrate to an inhibitor of its guaninenucleotide exchange factor eIF2B. As GTP binding is a prerequisite for Met-tRNA i Met binding to eIF2, GCN2 phosphorylation of eIF2 impairs TC formation. The reduction in TC levels, in turn, causes ribosomes, following translation of uORF1, to scan for a longer time and thus longer distance on the GCN4 mRNA before re-binding a TC and becoming competent to initiate translation. The scanning ribosomes traverse past the inhibitory uORFs2-4 without initiating, and then acquire a TC and initiate translation at the GCN4 start codon. In the absence of eIF2 phosphorylation, such as in yeast lacking GCN2, mutations that impair TC formation or TC binding to the ribosome can also stimulate GCN4 expression, conferring a general control derepressed (Gcd − ) phenotype (26, 27) . To quantify the impact of the eIF2␥ mutations on GCN4 expression, a GCN4-lacZ re- porter was introduced into the gcn2Δ strains expressing WT or mutant forms of eIF2␥ . While the eIF2␥ -V281T mutation slightly elevated GCN4-lacZ expression in our previous report (9) , the eIF2␥ -V281T mutation did not significantly impact GCN4-lacZ expression in this analysis, consistent with WT growth rate of strains expressing this mutant form of eIF2␥ . In contrast, the eIF2␥ -V281K mutation, which caused a significant slow-growth phenotype, resulted in an ∼8-fold increase in GCN4-lacZ expression compared to cells expressing WT eIF2␥ (Figure 2A ) (9) . Cells expressing the eIF2␥ -I318L mutant displayed a modest increase in GCN4-lacZ expression, while the most substantial GCN4 derepression was observed for the eIF2␥ -I318M mutation with a 16-fold increase in GCN4-lacZ expression (Figure 2A) . Expression of ATF4, the human homolog of GCN4, is also controlled by TC levels through regulated translation reinitiation at uORFs in the ATF4 mRNA leader. As in the GCN4 mRNA, the 40S ribosomal subunit readily resumes scanning following translation of uORF1 in the ATF4 mRNA. The ATF4 uORF2, which overlaps the 5 end of the ATF4 mORF, but in a different reading frame, functionally replaces the inhibitory uORFs2-4 in the GCN4 mRNA. Under conditions of high TC levels, ribosomes initiate at uORF2 and fail to synthesize ATF4; whereas, when TC levels are lower, ribosomes bypass uORF2 and translate the ATF4 mORF (28, 29) . To quantify the impact of the MEHMO syndrome mutation on ATF4 expression, HEK293T cells were co-transfected with an ATF4-luc reporter and an overexpression vector encoding either WT human eIF2␥ or eIF2␥ -I259M. Overexpression of WT eIF2␥ resulted in ATF4-luc expression similar to cells transfected with an empty vector control, while overexpression of eIF2␥ -I259M derepressed ATF4-luc expression by nearly 2-fold ( Figure 2B ). Taken together, these results suggest that the yeast I318M and human I259M mutations in eIF2␥ impair TC formation or TC binding to the scanning ribosome.
In addition to modulating GCN4 expression, mutations that impair eIF2 function have also been found to reduce the stringency of start codon selection (8) . Mutations that weaken Met-tRNA i Met binding to eIF2 are thought to allow premature release of Met-tRNA i
Met from eIF2 and enable ribosomes to initiate translation at non-AUG codons (a suppressor of initiation (Sui − ) phenotype) (3, 5, 8) . To determine if the fidelity of start site selection is modulated in the eIF2␥ mutants, plasmid-borne HIS4-lacZ reporters with either an AUG or UUG start codon were introduced into the yeast strains expressing WT or mutant forms of eIF2␥ . As observed previously (30) , cells expressing WT eIF2␥ displayed a high level of stringency for start site selection with HIS4-lacZ expression from the UUG-initiated reporter at ∼2%, the level obtained from the AUG-initiated reporter ( Figure 2C ). While the UUG/AUG initiation ratio in cells expressing eIF2␥ -V281T and eIF2␥ -I318L were not significantly different from cells expressing WT eIF2␥ , consistent with the mild phenotypes of these mutations in the growth and GCN4 expression studies, both the V281K and I318M mutations increased the UUG/AUG initiation ratio by ∼2.5-fold ( Figure 2C ). This reduction in the stringency of start codon selection further supports the notion that the eIF2␥ -I318M mutation impairs TC integrity, perNucleic Acids Research, 2019, Vol. 47, No. 2 861 haps lowering the fidelity of start site selection by prematurely releasing Met-tRNA i Met at non-AUG codons during the ribosome scanning process.
Overexpression of tRNA i Met suppresses the slow growth phenotype in yeast expressing eIF2␥-I318M
As our structural analysis indicated that the I259M mutation might disrupt TC integrity by impairing Met-tRNA i Met binding to the eIF2 complex, we next tested whether overexpression of tRNA i
Met could suppress the slow-growth and translation initiation phenotypes observed for the analogous eIF2␥ -I318M mutant in yeast. High copy-number plasmids encoding yeast eIF2␣ (SUI2), eIF2␤ (SUI3), tRNA i Met (IMT4), or an empty vector control were introduced into yeast strains expressing WT eIF2␥ , eIF2␥ -V281K or eIF2␥ -I318M. Cells expressing WT eIF2␥ and overexpressing either eIF2␣ or tRNA i
Met grew similarly to the vector control, while overexpression of eIF2␤ resulted in a slight growth defect as previously reported (Figure 3A , rows 1-4) (16). Consistent with the growth defects noted in Figure 1E , the empty vector transformants of both the eIF2␥ -V281K and eIF2␥ -I318M mutants exhibited severe slow-growth phenotypes ( Figure 3A , rows 5 and 9) (9). As we reported previously, the eIF2␥ -V281K mutation impairs eIF2␤ binding to eIF2␥ (9) . In accord with this eIF2 complex assembly defect, overexpression of eIF2␤, but not eIF2␣ or tRNA i Met , partially suppressed the slowgrowth phenotype of the eIF2␥ -V281K mutant ( Figure 3A , row 7) by restoring eIF2 complex levels (9) . In contrast to the eIF2␥ -V281K mutant, overexpression of eIF2␤ exacerbated the growth defect of the eIF2␥ -I318M mutant (Figure 3A, row 11 ). The cause of this enhanced growth defect is unclear. Intriguingly, overexpression of tRNA i
Met restored the growth of the eIF2␥ -I318M mutant to near WT levels ( Figure 3A, row 12) . As western analyses indicated that overexpression of eIF2␣, eIF2␤ or tRNA i Met did not affect the levels of the WT or mutant eIF2␥ proteins ( Figure 3B ), we propose that overexpression of tRNA i Met suppresses the growth defect of the eIF2␥ -I318M mutant by restoring eIF2 TC formation.
To further explore the role of tRNA i Met in modulating eIF2␥ -I318M function, GCN4-lacZ reporter activity was analyzed in yeast cells expressing WT eIF2␥ , eIF2␥ -V281K or eIF2␥ -I318M with either a vector control or tRNA i Met overexpression. In accordance with our earlier observation, both the V281K and I318M mutations in eIF2␥ caused robust derepression of GCN4-lacZ expression ( Figure 4A , white bars). Additionally, overexpression of tRNA i
Met dampened the level of GCN4 expression by roughly 50% in both the eIF2␥ -V281K and eIF2␥ -I318M strains ( Figure 4A , black bars). These data suggest that tRNA i
Met overexpression is likely sufficient to drive an increase in eIF2 TC formation by mass action in both the eIF2␥ -V281K and eIF2␥ -I318M mutant cells.
We next assessed the impact of tRNA i Met overexpression on start codon selection stringency in the yeast strains expressing WT eIF2␥ , eIF2␥ -V281K or eIF2␥ -I318M. As we observed above, both the eIF2␥ -V281K and eIF2␥ -I318M mutations elevated the UUG/AUG initiation ratio, indicating impaired fidelity of start codon selection ( Figure 4B , white bars). Interestingly, overexpression of tRNA i Met did not attenuate the increase in UUG-lacZ expression in either of the eIF2␥ mutants ( Figure 4B , black bars). As will be discussed in more detail below, the translation start site fidelity defect in the eIF2␥ -I318M mutant was likely due to premature release of eIF2, but not Met-tRNA i Met , from the scanning ribosome. Accordingly, overexpression of tRNA i Met and the attendant increase in TC levels was not expected to impact start site selection. Met (IMT4). Means and standard deviations of ␤-galactosidase activities were calculated for three independent transformants. Statistically significant differences in ␤-galactosidase activities for strains expressing mutant versus WT eIF2␥ with empty vector (*) or for strains overexpressing tRNA i Met versus empty vector (#) are indicated and were calculated using a Student's t-test with a P-value threshold of P = 0.05. eIF2␥ ) in the aIF2 TC ( Figure 1A-C) , the altered GCN4 mRNA translation in the eIF2␥ -I318M mutant cells (Figure 2A) , and the co-suppression of the cell growth and GCN4 expression defects in the mutant by overexpression of tRNA i Met ( Figures 3A and 4A) , we hypothesized that the I318M mutation impaired Met-tRNA i Met binding to eIF2. To assess the impact of the eIF2␥ -I318M mutation on eIF2 complex integrity and TC formation, we first examined co-precipitation of the eIF2␣ and eIF2␤ subunits with His-tagged WT eIF2␥ or eIF2␥ -I318M. As controls, the assays were also performed using extracts from strains expressing untagged eIF2␥ or His-tagged eIF2␥ -V281K. Whereas no eIF2 subunits were precipitated with Ni 2+ affinity resin from the lysates of cells expressing untagged eIF2␥ ( Figure 5A , lane 5), both eIF2␣ and eIF2␤ were readily coprecipitated with His-tagged WT eIF2␥ ( Figure 5A , lane 6). The eIF2␥ -V281K mutation, as reported previously (9), impaired eIF2␤, but not eIF2␣, binding to eIF2␥ (Figure 5A, lane 8) ; however, the eIF2␥ -I318M mutant pulleddown eIF2␣ and eIF2␤ to the same extent as WT eIF2␥ ( Figure 5A, lane 7) . Thus, the eIF2␥ -I318M mutation did not affect eIF2 complex formation. We next used the same co-precipitation assays to assess TC formation by monitoring the pulldown of Met-tRNA i Met with the eIF2 complexes. Total RNA was isolated from the pellets of the pulldown assays and RT-PCR was used to specifically amplify tRNA i Met as described in the 'Materials and Methods' section. As shown in the bottom panel of Figure 5A , His-tagged eIF2␥ -V281K pulled down lower levels of MettRNA i
Met than WT eIF2␥ , a downstream consequence of reduced eIF2 heterotrimer formation in the eIF2␥ -V281K mutant ( Figure 5A, lanes 6 and 8) . The I318M mutation had a much more profound impact on TC levels with substantially reduced amounts of Met-tRNA i Met pulled down with the eIF2␥ -I318M mutant ( Figure 5A, lane 7) , indicating a defect in TC formation.
To further examine the impact of the eIF2␥ -I318M mutation on TC formation, we purified the eIF2 complexes from strains expressing either WT eIF2␥ or the eIF2␥ -I318M mutant. Figure 5B ), which is comparable to the value obtained in previous reports (24, 21) . Intriguingly, the purified eIF2 complexes containing eIF2␥ -I318M bound Met-tRNA i Met with ∼5-fold lower affinity (K d = 98 ± 10 nM). As the binding of GTP and Met-tRNA i Met to eIF2 are thermodynamically coupled, the apparent Met-tRNA i Met binding defect observed for the eIF2 complexes containing eIF2␥ -I318M could be due to a defect in guanine nucleotide or in MettRNA i Met binding. Because eIF2 has a higher affinity for GDP than for GTP (24), we used filter binding assays to monitor [ 3 H]GDP binding to eIF2 as a means to examine the impact of the eIF2␥ mutation on guanine nucleotide binding. As shown in Figure 5C , the eIF2 complexes containing WT eIF2␥ (
3 H]GDP with similar affinities that were comparable to previously reported measurements for WT eIF2 (24, 21) . Thus, the Met-tRNA i Met binding defect associated with the eIF2␥ -I318M mutation is not due to a defect in guanine nucleotide binding. Taken together, the data from the pulldown assays and the in vitro binding assays indicate that the eIF2␥ -I318M mutation in yeast eIF2, and by analogy the corresponding eIF2␥ -I259M mutation identified in the patient with MEHMO syndrome, impairs eIF2 TC integrity through a defect in Met-tRNA i Met binding. Based on the co-suppression of cell growth and GCN4 expression defects in the eIF2␥ -I318M mutant by overexpression of tRNA i Met ( Figures 3A and 4A ), we hypothesized that tRNA i Met overexpression is likely sufficient to drive an increase in eIF2 TC formation by mass action. To assess the impact of tRNA i Met overexpression on TC formation, we introduced a high copy-number plasmid encoding yeast tRNA i Met or empty vector control into yeast strains expressing WT eIF2␥ , eIF2␥ -I318M or eIF2␥ -V281K and 1-4) or incubated with Ni-NTA resin (His-eIF2␥ pull-down; lanes 5-8). Input and pull-down protein samples were subjected to SDS-PAGE followed by immunoblotting (western blot, WB) with rabbit polyclonal antisera against yeast eIF2␥ , eIF2␤ and eIF2␣. Input and pull-down RNA samples were subjected to RT-PCR using oligonucleotide primers specific to yeast tRNA i Met , and reaction products were resolved by gel electrophoresis. The asterisk (*) indicates a non-specific immunoblot band migrating faster than eIF2␥ . Met were either immediately processed (Input; lanes 1-8) or incubated with Ni-NTA resin (His-eIF2␥ pull-down; lanes 9-16). Input and pull-down protein samples were subjected to SDS-PAGE followed by immunoblotting (western blot, WB) with rabbit polyclonal antisera against yeast eIF2␥ , eIF2␤ or eIF2␣. Input and pull-down RNA samples were subjected to RT-PCR using oligonucleotide primers specific to yeast tRNA i Met , and reaction products were resolved by gel electrophoresis.
then examined co-precipitation of eIF2␣, eIF2␤ and MettRNA i Met with His-tagged eIF2␥ . Strains expressing untagged eIF2␥ were utilized as a negative control, and no eIF2 TC components were precipitated with Ni 2+ affinity resin from the lysates of cells expressing untagged eIF2␥ ( Figure 5D, lanes 9 and 10) . eIF2␣, eIF2␤ and MettRNA i
Met were readily co-precipitated with His-tagged WT eIF2␥ independent of tRNA i Met overexpression ( Figure  5D, lanes 11 and 12) . As observed previously ( Figure 5A ), reduced levels of eIF2␤ and Met-tRNA i
Met , but not eIF2␣, were co-precipitated with the eIF2␥ -V281K mutant (Figure 5D, lane 15) . Overexpression of tRNA i
Met slightly elevated Met-tRNA i Met binding to eIF2␥ -V281K ( Figure 5D , lanes 15 and 16), consistent with the partial suppression of the GCN4 expression defects in the eIF2␥ -V281K mutant by overexpression of tRNA i Met ( Figure 4A ). The eIF2␥ -I318M mutant did not affect eIF2 heterotrimer formation, as WT eIF2␥ and eIF2␥ -I318M pulled down similar amounts of both the eIF2␣ and eIF2␤ subunits ( Figure 5D , lanes [11] [12] [13] [14] . However, the I318M mutation substantially impaired Met-tRNA i Met binding ( Figure 5D , lane 13), and co-precipitation of Met-tRNA i
Met with eIF2␥ -I318M was restored in cells overexpressing tRNA i Met ( Figure 5D , lanes 13 and 14). Thus, overexpression of tRNA i
Met is sufficient to drive an increase in eIF2 TC formation by mass action in the eIF2␥ -I318M mutant cells.
DISCUSSION
In this study, we address the molecular defect in eIF2 function caused by the eIF2␥ -I259M mutation originally identified in a patient with MEHMO syndrome. Based on the location of the corresponding I318 residue in yeast eIF2␥ ( Figure 1D ) and I218 residue in Ss aIF2␥ ( Figure 1C) , we proposed that the mutation might impact Met-tRNA i Met binding to eIF2. Consistent with this hypothesis, substitution of Met for I259 in a human eIF2␥ overexpression construct or for I318 in yeast eIF2␥ resulted in derepression of ATF4 or GCN4 expression, respectively, which are sensitive in vivo reporters of eIF2 TC levels. The yeast eIF2␥ -I318M mutation also lowered the stringency of start codon selection. Finally, biochemical studies revealed reduced binding of Met-tRNA i Met to the mutant eIF2 complexes both in crude yeast extracts and with the purified protein. Taken together these studies reveal that defective Met-tRNA i Met binding to eIF2 is a cause of MEHMO syndrome.
To date, four mutations in eIF2␥ have been linked to MEHMO syndrome. While severely affected patients exhibit all MEHMO symptoms (Mental deficiency, Epilepsy, Hypogenitalism, Microcephaly and Obesity), less affected patients exhibit only a subset of symptoms. It is interesting to speculate that the impact of the mutations on distinct functions of eIF2␥ may play a critical role in determining the phenotype and symptom severity of patients with MEHMO syndrome. Substitution of Thr for I222 on the back side of the GTP-binding domain of eIF2␥ impaired eIF2 complex integrity by disrupting binding of the eIF2␤ subunit to eIF2␥ (9) . The corresponding yeast eIF2␥ -V281T mutation caused a slight elevation in GCN4 expression (9), though not statistically significant in this report (Figure 2A) , and a modest increase in translation initiation at a near cognate UUG codon (9) . The milder phenotypes in the yeast eIF2␥ -V281T versus the eIF2␥ -I318M mutant is consistent with the more severe symptoms in the patient with the eIF2␥ -I259M mutation. In further support of this correlation between yeast phenotypes and symptoms in patients, an S108R mutation near a Zn 2+ binding element in eIF2␥ resulted in a somewhat milder form of MEHMO syndrome and the corresponding D167R mutation in yeast had no impacts on cell growth or reporter gene expression (12) . The fourth mutation in eIF2␥ identified in patients with MEHMO syndrome, eIF2␥ -I465Sfs*4, substitutes three new residues in place of the native eight Cterminal residues in eIF2␥ . While a molecular explanation for how this mutation impacts eIF2 function has not been revealed, the corresponding mutation at the C-terminus of yeast eIF2␥ mimicked the effects of the V281T mutation. A fifth eIF2␥ mutation was identified upon resequencing samples from patients with undefined XLID. A V151L mutation was identified in a patient; however, because of the nature of the study it has not been possible to determine whether the mutation is linked to MEHMO syndrome. Despite this limitation, it is noteworthy that the corresponding V210L mutation in yeast eIF2␥ resulted in a 12-fold increase in GCN4-lacZ expression and a 4-fold increase in the UUG/AUG initiation ratio (9) . While the impacts of mutations in eIF2 on cell growth and reporter assays in single-celled yeast would not be expected to perfectly correlate with the severity of tissue-specific symptoms in patients with the corresponding mutations, our studies have demonstrated that yeast serves as a good system to model the eIF2␥ mutations identified in patients with MEHMO syndrome.
The studies of the eIF2␥ -I222T mutant revealed that defects in eIF2 heterotrimer formation could cause MEHMO syndrome (9) . The I222T mutation lies in a cavity that forms the docking site for eIF2␤ to bind to eIF2␥ . Consistent with this location, the mutation impaired eIF2␤ association with eIF2␥ and the growth defect in yeast expressing the corresponding mutation could be suppressed by overexpression of eIF2␤ (9), as shown for the related mutation eIF2␥ -V281K in Figure 3A . The eIF2␥ -I318M mutation does not impair eIF2 heterotrimer formation ( Figure 5A ), but instead impairs the binding of Met-tRNA i Met to eIF2 ( Figure  5 ). Examination of the structures of the isolated archaeal aIF2-GTP-Met-tRNA i Met TC ( Figure 1A -C) and the analogous yeast eIF2-GTP-Met-tRNA i Met complex bound to the 40S subunit ( Figure 1D ) reveals that the I318 residue in yeast eIF2␥ (and by analogy the I259 residue in human eIF2) lies near the methionine-binding site. A cluster of 12 residues forms a shell around the methionine docking site on eIF2␥ ( Figure 1D ). Mutational studies in yeast have implicated four of these residues in Met-tRNA i Met binding to eIF2. The yeast eIF2␥ mutations Y142H and G397A were previously isolated in screens for mutants that derepress GCN4 expression (4, 31) . In addition, both of these mutations reduce the fidelity of translation start site selection causing increased UUG/AUG ratios (4). Consistent with these genetic phenotypes, the slow-growth phenotype of yeast expressing eIF2␥ -G397A was suppressed by overexpression of tRNA i Met (32) and the Y142H mutation in eIF2␥ was shown to impair Met-tRNA i Met binding to pu- rified eIF2 in vitro (33) . As shown in this study, the slowgrowth phenotype associated with eIF2␥ -I318M mutation was suppressed by overexpression of tRNA i Met ( Figure 3A ) and the purified eIF2 complex containing eIF2␥ -I318M was defective for binding Met-tRNA i Met ( Figure 5 ). While the I318 residue is not in the shell of residues that directly form the Met binding pocket in eIF2␥ (Figure 1D ), the adjacent residue R319 ( Figure 1D) is part of the Met binding pocket and mutation of R319 to Asp is lethal in yeast (32) . We propose that the eIF2␥ -R319D mutation impairs Met recognition and that the adjacent eIF2␥ -I318M mutation described in this study impairs Met-tRNA i Met binding indirectly by impacting the position of R319 and its ability to contribute to Met recognition and binding. As all 12 residues forming the Met binding pocket in eIF2␥ are well conserved in evolution, it is tempting to speculate that this conservation is driven by the requirement to initiate translation with Met. While mutations in the Met recognition pocket might enable eIF2 to bind alternate elongator aminoacyl-tRNAs and thereby initiate translation with residues other than Met, which could be of interest in biotechnology, the critical roles played by conserved tRNA i
Met residues in translation start site selection (34) indicate that simply relaxing the stringency of Met binding is not likely to enable initiation with alternate aminoacyltRNAs.
The defect in Met-tRNA i Met binding and the accompanying reduced levels of eIF2 TCs in yeast expressing eIF2␥ -I318M readily accounts for the elevated GCN4 expression. As previously demonstrated (27, (16) (17) , regulated translation reinitiation at the uORFs on the GCN4 mRNA inversely couple GCN4 synthesis to TC levels. Consistent with this idea, overexpression of tRNA i Met in the eIF2␥ -I318M mutant, which through mass action elevates TC levels ( Figure 5D ), suppresses the induction of GCN4 expression ( Figure 4A ). In contrast, overexpression of tRNA i Met failed to restore start codon selection stringency in the eIF2␥ -I318M mutant ( Figure 4B ). This differential effect of overexpression of tRNA i Met on GCN4 expression and start codon selection stringency in the eIF2␥ -I318M mutant (Figure 4 ) likely reflects the ordered pathway of translation initiation. As the TC must bind to the 40S subunit prior to mRNA binding and start codon selection, the stringency of start site selection is not expected to be sensitive to TC levels. Thus, restoring TC levels in the eIF2␥ -I318M mutant failed to suppress near cognate initiation. However, this raises the question of how defects in TC formation relax the stringency of start codon selection in the eIF2␥ -I318M mutant. One possibility is that the lowered affinity of eIF2␥ -I318M for Met-tRNA i
Met results in premature release of eIF2, but not Met-tRNA i Met , from the scanning ribosome. This might then allow the Met-tRNA i Met to move from its initial binding site in the P out location that is conducive to ribosome scanning and transient inspection of the mRNA sequence for a start codon to a more fully engaged P in location that prevents further scanning and marks selection of the translation start codon (AUG or near cognate) (1) (2) (3) . A second possibility is that the I318M mutation might have a greater impact on Met-tRNA i Met binding to eIF2 in the P out versus P in state. Greater destabilization of the P out state would shift the equilibrium to the P in state and reduce the stringency of start codon selection. However, these simple models do not account for the critical role of eIF1 in translation start site selection. Genetic, biochemical and structural studies have established that eIF1 acts as a gatekeeper to block P i and subsequently eIF2-GDP release until a codon-anticodon match is established between the mRNA and Met-tRNA i Met in the P site of the ribosome (1,2,35-43 ). Considering this critical role of eIF1, the eIF2␥ mutation might relax start codon selection stringency by either enabling eIF2 release prior to eIF1 release or by prompting premature release of eIF1 in the absence of perfect anticodon-codon complementarity. The latter model was previously invoked to explain the relaxed start codon selection stringency of eIF2␥ mutants that do not affect Met-tRNA i Met binding affinity (5) . Accordingly, it was proposed that the eIF2␥ mutations alter the positioning of Met-tRNA i Met in the P site to provoke eIF1 release at near cognate start codons (5) . Perhaps the eIF2␥ -I318M mutation in addition to weakening Met-tRNA i Met binding, alters the conformation of Met-tRNA i Met on the scanning ribosome to enable selection of a near cognate start codon and release of eIF1 in the absence of perfect base-pairing complementarity between the mRNA codon and the anticodon of tRNA i
Met . Finally, it is intriguing to compare the impacts of mutations in eIF2␥ with mutations in the guanine nucleotide exchange factor eIF2B (44) . eIF2B plays a critical role in determining eIF2 TC levels by regulating the levels of GTPbound eIF2 (45) . Following selection of the translation start codon by the scanning PIC, eIF2 completes hydrolysis of the bound GTP and P i is released (2) . Subsequently, eIF2 in complex with GDP is released from the PIC. In order for eIF2 to participate in additional rounds of translation initiation, the GDP bound to eIF2 must be exchanged by GTP in a reaction catalyzed by eIF2B (1) . Mutations have been identified in each of the five subunits of eIF2B that cause leukoencephalopathy with vanishing white matter (VWM) (44, 45) . The symptoms associated with MEHMO syndrome and VWM have some overlap, as a subset of patients with MEHMO syndrome also have decreased white matter in their brains (9) (10) (11) . Furthermore, yeast models of VWM and MEHMO syndrome mutations exhibit similar phenotypes with impaired cell growth and increased GCN4 expression, indicative of decreased eIF2 TC levels ( Figures  1E and 2A) (9, 44, 46) . However, it is also noteworthy that symptom presentation occurs earlier in the pathogenesis of MEHMO syndrome than VWM disease, and that eIF2␥ mutations affect a broad spectrum of tissues that are not impacted by mutations in eIF2B (9) (10) (11) 44, 46) . While it is unclear why mutations in two essential translation initiation factors result in the different symptoms described for MEHMO syndrome and VWM, one possibility is that impaired translation start site selection, as described here and in our previous analyses of MEHMO syndrome mutations, underlies the additional phenotypes observed in patients with MEHMO syndrome (Figures 2C and 4B) (9) . Whereas VWM mutations impair eIF2B activity and are proposed to cause disease due to low eIF2 TC levels (46, 47) , MEHMO syndrome mutations result in dysregulation of translation initiation through both decreased eIF2 TC levels and reduced start codon selection stringency. How the molecular differences between eIF2␥ and eIF2B mutations promote distinct patient phenotypes, and how mutations in eIF2␥ , a ubiquitously expressed translation initiation factor, result in the tissue-specific phenotypes associated with MEHMO syndrome will be critical questions to address in future studies.
